title: [Sulperazone in the treatment of severe infections in patients with cancer].
abstract: For the evaluation of rational sulperazone position in oncological hospital and elaboration of its implementation criteria investigation was performed. The trial included 193 patients (88 patients with injuries, 66 with hospital pneumonia, 39 with urinary track infection). From different clinical material of the patients were isolated 136 straines of Gram-negative bacteria. Suseptibile to sulperazone were 67 per cent of P. aeruginosa, 78-86 per cent of P. vulgaris, Klebsiella and E. coli isolates, 66 [symbol: see text] 60 per cent of Enterobacter and Serratia isolates subsequently. Comparative results of treatment with sulperazone as monotherapy and for combination with aminoglycosides (gentamycin or amicacin) in the case of P. aeruginosa infection demonstrated high sulperazone efficacy not lower than imipenem/cilsatatin and cefepime efficacy in the case of hospital infections treatment at critical care units. Low price of the sulperazone treatment when compared to imipenem/cilastatine is emphasized. Another advantage of sulperazone when compared to cefepime is anaerobic infection treatment--cefepime is administered in combination with metronidazole while sulperazone is used in monotherapy.
authors.affiliation: Municipal Clinical Oncological Hospital No. 62, Moscow.
authors.forename: S D
authors.initials: SD
authors.lastname: Mitrokhin
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002438:Cefoperazone / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006090:Gram-Negative Bacteria / Q000145:classification / Q000187:drug effects*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000628:therapy*; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology; D013407:Sulbactam / Q000627:therapeutic use*; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000382:microbiology; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D002438:Cefoperazone; C057923:sulperazone; D013407:Sulbactam